Global Age-Related Macular Degeneration (AMD) Market Size, Share, Development, Growth and Demand Forecast to 2022 - Industry Insights by Type (Dry AMD, and Wet AMD), by Drug (Lucentis, Eylea, Visudyne, Avastin and Others)

  • ID: 3744029
  • Report
  • Region: Global
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • Acucela
  • Alimera Sciences, Inc.
  • Bayer Ag.
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline Plc
  • Novartis Ag
  • MORE
The global age-related macular degeneration market accounted for revenue of $5,335.7 million in 2015, and it is expected to grow at a CAGR of 7.6% during 2016 - 2022. Among the various types, the wet AMD segment is expected to witness the faster growth during the forecast period. The global age-related macular degeneration market is growing at a significant rate, due to growing geriatric population, and increasing prevalence of age-related macular degeneration. In addition, increasing prevalence of lifestyle associated diseases such as obesity and hypertension, increasing healthcare expenditure and increasing pipeline drugs for AMD are also driving the growth of the global age-related macular degeneration market.

Age-related macular degeneration (AMD) is an acquired retinal disorder indicated by fundus changes. It is one of the most common forms of visual impairment in the geriatric population. It is a deterioration or degeneration of macular, leading to vision loss among people aged 60 years and above. The macula is a small part of retina responsible of sharpness and central vision.

AMD is mainly of two types - dry and wet AMD. Dry AMD is caused due to formation of deposits called drusen under the retina; whereas, wet AMD is caused due to abnormal growth of the blood vessels from the choroid beneath the macula. Most of the patients suffer from dry AMD; however, the dry form of AMD may lead to wet form AMD.

The restraints associated with the growth of the global age-related macular degeneration market include stringent regulatory requirements and increase in off label use. The increasing awareness of AMD is the key trend observed in the global age-related macular degeneration market.

Geographically, North America is expected to maintain dominance in the global market of age-related macular degeneration during 2016 - 2022. This is due to increasing prevalence of hypertension and obesity and increased healthcare spending. In addition, increasing awareness of AMD and increasing pipeline products of AMD, and higher drug treatment rate is also supporting the growth of the age-related macular degeneration market in North America. The North American AMD market is witnessing rapid increase due to increase in geriatric population, which started witnessing more demand for treatment. According to the UN publication, “World Population Ageing 2013”, in 2013, approximately 70,571,000 people were aged 60 years or above in North America, which accounted for 19.9% share of its total population.

The European age-related macular degeneration market is growing, mainly due to growing aging population, increasing prevalence of lifestyle associated disease, and increasing healthcare cost. However, the Asia-Pacific market of age-related macular degeneration is expected to witness the highest growth globally, during the forecast period. This is due to growing geriatric population and upsurge in the occurrence rate of different AMD. Additionally, increasing healthcare spending and increasing prevalence of lifestyle associated diseases are driving the growth of the market in the region.

Some of the key companies operating in the global age-related macular degeneration market include Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Regeneron Pharmaceutical, Inc., Acucela, Ophthotech Corporation, Neurotech Pharmaceuticals, Inc., GlaxoSmithKline plc, StemCells Inc and Alimera Sciences, Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acucela
  • Alimera Sciences, Inc.
  • Bayer Ag.
  • F. Hoffmann-La Roche Ltd
  • Glaxosmithkline Plc
  • Novartis Ag
  • MORE
1. Research Scope and Methodology
1.1 Market Definition
1.2 Market Scope
1.2.1 Global Amd Market Breakdown by Type
1.2.2 Global Amd Market Breakdown by Drug
1.2.3 Global Amd Market Breakdown by Geography
1.3 Research Methodology and Sources

2. Executive Summary
2.1 Key Findings
2.2 Research Summary

3. Market Outlook
3.1 Introduction
3.1.1 Diagnosis of Amd
3.1.2 Stages of Amd
3.1.3 Treatment of Amd
3.1.4 Various Drugs for The Treatment of Amd
3.1.4.1 Lucentis
3.1.4.2 Eylea
3.1.4.3 Avastin
3.1.4.4 Visudyne
3.2 Trends in The Market
3.2.1 Increasing Awareness of Amd
3.3 Factors Driving Growth of The Market and its Impact on Market Forecast
3.3.1 Growing Geriatric Population
3.3.2 Increasing Prevalence of Amd
3.3.3 Increasing Prevalence of Lifestyle Associated Diseases
3.3.4 Increasing Pipeline Drugs for Amd
3.3.5 Increasing Healthcare Cost
3.3.6 Impact Analysis of Drivers on Market Forecast
3.4 Factors Hindering The Growth of The Market and its Impact on Market Forecast
3.4.1 Increase in Off Label Use
3.4.2 Stringent Regulatory Requirements
3.4.3 Impact Analysis of Restraints on Market Forecast

4. Drug Approval Process in The U.S. and Eu
4.1 Drug Approval Process in The U.S.
4.2 Drug Approval Process in The Eu

5. Global Age-Related Macular Degeneration Market Size and Forecast (2012 - 2022)
5.1 Global Amd Market, by Type
5.2 Global Amd Market, by Drug
5.3 Global Amd Market, by Region

6. Global Age-Related Macular Degeneration Market, by Type
6.1 Dry Amd Market
6.2 Wet Amd Market

7. Global Age-Related Macular Degeneration Market, by Geography
7.1 North America Amd Market
7.1.1 North America Amd Market, by Type
7.1.2 North America Amd Market, by Country
7.2 Europe Amd Market
7.2.1 Europe Amd Market, by Type
7.2.2 Europe Amd Market, by Country
7.3 Asia-Pacific Amd Market
7.3.1 Asia-Pacific Amd Market, by Type
7.3.2 Asia-Pacific Amd Market, by Country
7.4 Rest of The World (Row) Amd Market
7.4.1 RoW Amd Market, by Type

8. Competitive Positioning Analysis
8.1 Porter’s Five Forces of Competitive Position Analysis
8.1.1 Bargaining Power of Buyers
8.1.2 Bargaining Power of Suppliers
8.1.3 Threat of New Entrants
8.1.4 Intensity of Rivalry
8.1.5 Threat of Substitutes
8.2 Pipeline Analysis of Amd Drugs

9. Company Profiles and Strategic Developments
9.1 Key Company Profiles
9.1.1 Novartis Ag
9.1.1.1 Business Overview
9.1.1.2 Product and Service Offerings
9.1.2 F. Hoffmann-La Roche Ltd
9.1.2.1 Business Overview
9.1.2.2 Product and Service Offerings
9.1.3 Bayer Ag.
9.1.3.1 Business Overview
9.1.3.2 Product and Service Offerings
9.1.4 Regeneron Pharmaceutical, Inc.
9.1.4.1 Business Overview
9.1.4.2 Product and Service Offerings
9.1.5 Acucela
9.1.5.1 Business Overview
9.1.5.2 Product and Service Offerings
9.1.6 Ophthotech Corporation
9.1.6.1 Business Overview
9.1.6.2 Product and Service Offerings
9.1.7 Neurotech Pharmaceuticals, Inc.
9.1.7.1 Business Overview
9.1.7.2 Product and Service Offerings
9.1.8 Glaxosmithkline Plc
9.1.8.1 Business Overview
9.1.8.2 Product and Service Offerings
9.1.9 Stemcells Inc.
9.1.9.1 Business Overview
9.1.9.2 Product and Service Offerings
9.1.10 Alimera Sciences, Inc.
9.1.10.1 Business Overview
9.1.10.2 Product and Service Offerings
9.2 Strategic Developments in The Amd Market
9.2.1 Collaborations/ Partnerships
9.2.2 Product Approval/Launch
9.2.3 Merger and Acquisition
9.2.4 Other Developments

10. Appendix
10.1 List of Abbreviations

List of Tables
Table 1 Specific Primary and Secondary Sources Used for this Publication
Table 2 Global Amd Market Snapshot
Table 3 Some of The Pipeline Drugs of Amd in Major Companies
Table 4 Healthcare Expenditure As % of Gdp
Table 5 Drivers for The Market: Impact Analysis
Table 6 Restraints for The Market: Impact Analysis
Table 7 Global Amd Market, by Type, $M (2012 - 2015)
Table 8 Global Amd Market, by Type, $M (2016 - 2022)
Table 9 Global Amd Market, by Drug, $M (2012 - 2015)
Table 10 Global Amd Market, by Drug, $M (2016 - 2022)
Table 11 Global Amd Market, by Region, $M (2012 - 2015)
Table 12 Global Amd Market, by Region, $M (2016 - 2022)
Table 13 Global Dry Amd Market, by Region, $M (2012 - 2015)
Table 14 Global Dry Amd Market, by Region, $M (2016 - 2022)
Table 15 Global Wet Amd Market, by Region, $M (2012 - 2015)
Table 16 Global Wet Amd Market, by Region, $M (2016 - 2022)
Table 17 North America Amd Market, by Type, $M (2012 - 2015)
Table 18 North America Amd Market, by Type, $M (2016 - 2022)
Table 19 North America Amd Market, by Country, $M (2012 - 2015)
Table 20 North America Amd Market, by Country, $M (2016 - 2022)
Table 21 Europe Amd Market, by Type, $M (2012 - 2015)
Table 22 Europe Amd Market, by Type, $M (2016 - 2022)
Table 23 Europe Amd Market, by Country, $M (2012 - 2015)
Table 24 Europe Amd Market, by Country, $M (2016 - 2022)
Table 25 Asia-Pacific Amd Market, by Type, $M (2012 - 2015)
Table 26 Asia-Pacific Amd Market, by Type, $M (2016 - 2022)
Table 27 Asia-Pacific Amd Market, by Country, $M (2012 - 2015)
Table 28 Asia-Pacific Amd Market, by Country, $M (2016 - 2022)
Table 29 RoW Amd Market, by Type, $M (2012 - 2015)
Table 30 RoW Amd Market, by Type, $M (2016 - 2022)
Table 31 Novartis Ag - Key Facts
Table 32 F. Hoffmann-La Roche Ltd - Key Facts
Table 33 Bayer Ag - Key Facts
Table 34 Regeneron Pharmeceuticals, Inc. - Key Facts
Table 35 Acucela- Key Facts
Table 36 Ophthotech Corporation- Key Facts
Table 37 Neurotech Pharmaceuticals, Inc.- Key Facts
Table 38 Glaxosmithkline Plc - Key Facts
Table 39 Stemcells Inc.- Key Facts
Table 40 Alimera Sciences, Inc. Key Fact
List of Figures
Fig 1 Market Scope for Global Amd Market
Fig 2 Research Methodology for Global Amd Market
Fig 3 Anatomical Structure of An Eye
Fig 4 Cross Section of A Macula
Fig 5 Amsler Grid Test
Fig 6 Optical Coherence Tomography of An Eye
Fig 7 Innovation of Wet Amd Treatment
Fig 8 Aging Population As A Percentage of Total Population, in Major Countries
Fig 9 Prevalence of Overweight Men Aged 30 and Above, in % (2005 and 2015)
Fig 10 Prevalence of Overweight Women Aged 30 and Above, in % (2005 and 2015)
Fig 11 Basic Drug Development Procedure
Fig 12 Global Amd Market Size, $M (2012 - 2022)
Fig 13 Global Amd Market Size, by Type, $M (2012 - 2022)
Fig 14 Global Amd Market Size, by Drug, $M (2012 - 2022)
Fig 15 Global Amd Market Share, by Drug (2015 and 2022)
Fig 16 Global Amd Market Size, by Region, $M (2012 - 2022)
Fig 17 Global Amd Market Share, by Region (2015 and 2022)
Fig 18 Global Dry Amd Market Size, by Region, $M (2012 - 2022)
Fig 19 Global Wet Amd Market Size, by Region, $M (2012 - 2022)
Fig 20 Global Amd Market Size, by Geography (2022)
Fig 21 North America Amd Market Size, by Type, $M (2012 - 2022)
Fig 22 North America Amd Market Size, by Country, $M (2012 - 2022)
Fig 23 Europe Amd Market Size, by Type, $M (2012 - 2022)
Fig 24 Europe Amd Market Size, by Country, $M (2012 - 2022)
Fig 25 Asia-Pacific Amd Market Size, by Type, $M (2012 - 2022)
Fig 26 Asia-Pacific Amd Market Size, by Country, $M (2012 - 2022)
Fig 27 RoW Amd Market Size, by Type, $M (2012 - 2022)
Fig 28 Porter’s Five Forces of Competitive Position Analysis
Fig 29 Pipeline Analysis of Amd Drugs (2015)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Acucela
- Alimera Sciences, Inc.
- Bayer Ag.
- F. Hoffmann-La Roche Ltd
- Glaxosmithkline Plc
- Neurotech Pharmaceuticals, Inc.
- Novartis Ag
- Ophthotech Corporation
- Regeneron Pharmaceutical, Inc.
- Stemcells Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll